SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer-Reference-Cited by-同舟云学术

SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer

Published:2019-05-30 Issue:1 Volume:5 Page:
ISSN:2374-4677
Container-title:npj Breast Cancer
language:en
Short-container-title:npj Breast Cancer

Author:

Sinn Bruno V.^ORCID,Fu Chunxiao,Lau Rosanna,Litton Jennifer,Tsai Tsung-Heng,Murthy Rashmi,Tam Alda,Andreopoulou Eleni,Gong Yun,Murthy Ravi,Gould Rebekah,Zhang Ya,King Tari A.,Viale Agnes,Andrade Victor,Giri Dilip,Salgado Roberto,Laios Ioanna,Sotiriou Christos,Marginean Esmeralda C.,Kwiatkowski Danielle N.,Layman Rachel M.,Booser Daniel,Hatzis Christos,Vicente Valero V.,Fraser Symmans W.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology

Link

http://www.nature.com/articles/s41523-019-0111-0.pdf

Reference35 articles.

1. Rugo, H. S. et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J. Clin. Oncol. 34, 3069–3103 (2016).

2. Cardoso, F. et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann. Oncol. 25, 1871–1888 (2014).

3. Lower, E. E., Glass, E. L., Bradley, D. A., Blau, R. & Heffelfinger, S. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res. Treat. 90, 65–70 (2005).

4. Hoefnagel, L. D. et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 12, R75 (2010).

5. Amir, E. et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J. Clin. Oncol. 30, 587–592 (2012).

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EMBER creates a unified space for independent breast cancer transcriptomic datasets enabling precision oncology;npj Breast Cancer;2024-07-09

2. Calcification-associated molecular traits and therapeutic strategies in hormone receptor-positive HER2-negative breast cancer;Cancer Biology & Medicine;2024-04-09

3. Txnrd1 as a prognosticator for recurrence, metastasis and response to neoadjuvant chemotherapy and radiotherapy in breast cancer patients;Heliyon;2024-03

4. Experimental and clinical evidence in favour of an effective immune stimulation in ER-positive, endocrine-dependent metastatic breast cancer;Frontiers in Immunology;2024-01-25

5. A Novel Mathematical Approach for Analysis of Integrated Cell–Patient Data Uncovers a 6-Gene Signature Linked to Endocrine Therapy Resistance;Laboratory Investigation;2024-01